Skip to main content

Advertisement

SpringerLink
Log in

The Burden of Cost in Inflammatory Bowel Disease: A Medical Economic Perspective and the Future of Value-Based Care

  • Inflammatory Bowel Disease (M Regueiro, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To examine the quantifiable economic impact of inflammatory bowel disease (IBD), key cost drivers and determinants, and the impact of value-based care in IBD. Finally, we prognosticate on future directions and opportunities on healthcare economics in IBD.

Recent Findings

New value-based initiatives, technologically driven interventions, and quality improvement programs have demonstrated reductions in healthcare utilization and enhanced patient outcomes, and several have realized cost of care reductions.

Summary

IBD is a costly, chronic illness with unbalanced spending by a small proportion of individuals. Pharmaceutical costs are overtaking inpatient expenses as the primary cost driver. Value-based care initiatives including the IBD medical home, remote monitoring platforms such as myIBDcoach and Project Sonar, and learning healthcare networks exemplified by ImproveCareNow have all demonstrated successes in improving care quality, patient outcomes, and reduced healthcare spending in some populations. The future of value-based care in IBD is bright, with ample opportunities for model refinement, collaboration, and growth.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–78. https://doi.org/10.1016/S0140-6736(17)32448-0.

    Article  PubMed  Google Scholar 

  2. Rocchi A, Benchimol EI, Bernstein CN, Bitton A, Feagan B, Panaccione R, et al. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol. 2012;26(11):811–7. https://doi.org/10.1155/2012/984575.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012. https://doi.org/10.1053/j.gastro.2011.10.001.

    Article  Google Scholar 

  4. Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–7. https://doi.org/10.1038/nrgastro.2015.150.

    Article  PubMed  Google Scholar 

  5. Silverstein MD, Loftus J, Sandborn WJ, et al. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117(1):49–57. https://doi.org/10.1016/S0016-5085(99)70549-4.

    Article  PubMed  CAS  Google Scholar 

  6. Bernstein CN, Loftus EV, Ng SC, Lakatos PL, Moum B. Hospitalisations and surgery in Crohn’s disease. Gut. 2012;61(4):622–9. https://doi.org/10.1136/gutjnl-2011-301397.

    Article  PubMed  Google Scholar 

  7. Regueiro MD, McAnallen SE, Greer JB, Perkins SE, Ramalingam S, Szigethy E. The inflammatory bowel disease specialty medical home: a new model of patient-centered care. Inflamm Bowel Dis. 2016. https://doi.org/10.1097/MIB.0000000000000819.

    Article  Google Scholar 

  8. Thorpe KE. Factors accounting for the rise in health-care spending in the United States: the role of rising disease prevalence and treatment intensity. Public Health. 2006;120(11):1002–7. https://doi.org/10.1016/j.puhe.2006.09.001.

    Article  PubMed  Google Scholar 

  9. Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135(6):1907–13. https://doi.org/10.1053/j.gastro.2008.09.012.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Bounthavong M, Li M, Watanabe JH. An evaluation of health care expenditures in Crohn’s disease using the United States medical expenditure panel survey from 2003 to 2013. Res Soc Adm Pharm. 2017;13(3):530–8. https://doi.org/10.1016/j.sapharm.2016.05.042.

    Article  Google Scholar 

  11. Hay JH. Inflammatory bowel disease. J Clin Gastroenterol. 1992;14(4):309–17.

    Article  CAS  Google Scholar 

  12. Kawalec P. Indirect costs of inflammatory bowel diseases: Crohn’s disease and ulcerative colitis. A systematic review. Arch Med Sci. 2016;12(2):295–302. https://doi.org/10.5114/aoms.2016.59254.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31(7):693–707. https://doi.org/10.1111/j.1365-2036.2010.04234.x.

    Article  PubMed  CAS  Google Scholar 

  14. Solberg IC, Vatn MH, Høie O, Stray N, Sauar J, Jahnsen J, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5(12):1430–8. https://doi.org/10.1016/j.cgh.2007.09.002.

    Article  PubMed  Google Scholar 

  15. Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN study). Scand J Gastroenterol. 2009;44(4):431–40. https://doi.org/10.1080/00365520802600961.

    Article  PubMed  Google Scholar 

  16. Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn’s disease: a payor perspective. Am J Gastroenterol. 2000;95(8):1955–60. https://doi.org/10.1016/S0002-9270(00)01053-4.

    Article  PubMed  CAS  Google Scholar 

  17. Park KT, Colletti RB, Rubin DT, Sharma BK, Thompson A, Krueger A. Health insurance paid costs and drivers of costs for patients with Crohn’s disease in the United States. Am J Gastroenterol. 2016. https://doi.org/10.1038/ajg.2015.207.

    Article  CAS  Google Scholar 

  18. Bates DW, Saria S, Ohno-Machado L, Shah A, Escobar G. Big data in health care: using analytics to identify and manage high-risk and high-cost patients. Health Aff. 2014;33(7):1123–31. https://doi.org/10.1377/hlthaff.2014.0041.

    Article  Google Scholar 

  19. Loly C, Belaiche J, Louis E. Predictors of severe Crohn’s disease. Scand J Gastroenterol. 2008. https://doi.org/10.1080/00365520801957149.

    Article  CAS  Google Scholar 

  20. Limsrivilai J, Stidham RW, Govani SM, Waljee AK, Huang W, Higgins PDR. Factors that predict high health care utilization and costs for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2017. https://doi.org/10.1016/j.cgh.2016.09.012.

    Article  Google Scholar 

  21. Click B, Ramos Rivers C, Koutroubakis IE, et al. Demographic and clinical predictors of high healthcare use in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016. https://doi.org/10.1097/MIB.0000000000000763.

    Article  Google Scholar 

  22. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009. https://doi.org/10.1111/j.1365-2036.2009.04033.x.

    Article  CAS  Google Scholar 

  23. Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease - Modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008. https://doi.org/10.1111/j.1365-2036.2008.03709.x.

    Article  CAS  Google Scholar 

  24. Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012. https://doi.org/10.1038/ajg.2012.127.

    Article  Google Scholar 

  25. Targownik LE, Benchimol EI, Witt J, et al. The effect of initiation of anti-TNF therapy on the subsequent direct health care costs of inflammatory bowel disease. Inflamm Bowel Dis. 2019. https://doi.org/10.1093/ibd/izz063.

    Article  Google Scholar 

  26. Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut. 2014. https://doi.org/10.1136/gutjnl-2013-305607.

    Article  CAS  Google Scholar 

  27. Abou Khalil M, Boutros M, Nedjar H, Morin N, Ghitulescu G, Vasilevsky CA, et al. Incidence rates and predictors of colectomy for ulcerative colitis in the era of biologics: results from a provincial database. J Gastrointest Surg. 2018;22(1):124–32. https://doi.org/10.1007/s11605-017-3530-y.

    Article  PubMed  Google Scholar 

  28. Jeuring SFG, van den Heuvel TRA, Liu LYL, Zeegers MP, Hameeteman WH, Romberg-Camps MJ, et al. Improvements in the long-term outcome of Crohn’s disease over the past two decades and the relation to changes in medical management: results from the population-based IBDSL cohort. Am J Gastroenterol. 2017;112(2):325–36. https://doi.org/10.1038/ajg.2016.524.

    Article  PubMed  Google Scholar 

  29. Lazarev M, Uliman T, Schraut WH, Kip KE, Saul M, Regueiro M. Small bowel resection rates in Crohn’s disease and the indication for surgery over time: experience from a large tertiary care center. Inflamm Bowel Dis. 2010;16(5):830–5. https://doi.org/10.1002/ibd.21118.

    Article  PubMed  Google Scholar 

  30. Wegner SE. Measuring Value in Health Care: The Times, They Are A Changin’. N C Med J. 2016;77(4):276–8. https://doi.org/10.18043/ncm.77.4.276.

    Article  PubMed  Google Scholar 

  31. Berwick DM, Hackbarth AD. Eliminating waste in US health care. JAMA J Am Med Assoc. 2012. https://doi.org/10.1001/jama.2012.362.

    Article  Google Scholar 

  32. Melmed GY, Siegel CA, Spiegel BM, et al. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013;19(3):662–8. https://doi.org/10.1097/mib.0b013e31828278a2.

    Article  PubMed  Google Scholar 

  33. Donabedian A. Evaluating the quality of medical care. Reprinted 1966 article. Milbank Q. 2005;83(4):691–729. https://doi.org/10.1111/j.1468-0009.2005.00397.x.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Porter ME. What is value in health care? N Engl J Med. 2010. https://doi.org/10.1056/NEJMp1011024.

    Article  CAS  Google Scholar 

  35. Berry SK, Melmed GY. Quality indicators in inflammatory bowel disease. Intest Res. 2018;16(1):43–7. https://doi.org/10.5217/ir.2018.16.1.43.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Physician Quality Reporting System (PQRS) measures list. 2013.

  37. Kim AH, Roberts C, Feagan BG, et al. Developing a standard set of patient-centred outcomes for inflammatory bowel disease-an international, cross-disciplinary consensus. J Crohn's Colitis. 2018. https://doi.org/10.1093/ecco-jcc/jjx161.

    Article  Google Scholar 

  38. •• Regueiro M, Click B, Anderson A, et al. Reduced unplanned care and disease activity and increased quality of life after patient enrollment in an inflammatory bowel disease medical home. Clin Gastroenterol Hepatol. 2018. https://doi.org/10.1016/j.cgh.2018.04.007 This study assesses the impact of a novel value-based care initiative - the IBD Medical Home - and demonstrates reductions in healthcare utilization along with improvement in patient outcomes and quality of life.

    Article  Google Scholar 

  39. Regueiro M, Click B, Holder D, Shrank W, McAnallen S, Szigethy E. Constructing an inflammatory bowel disease patient–centered medical home. Clin Gastroenterol Hepatol. 2017. https://doi.org/10.1016/j.cgh.2017.05.026.

    Article  Google Scholar 

  40. Regueiro MD, McAnallen SE, Greer JB, Perkins SE, Ramalingam S, Szigethy E. The inflammatory bowel disease specialty medical home. Inflamm Bowel Dis. 2016. https://doi.org/10.1097/mib.0000000000000819.

    Article  Google Scholar 

  41. L. K, J.V. B, M. S, C. B, R. T, P. L-B. Project Sonar: Reduction in cost of care in an attributed cohort of patients with crohn’s disease. Gastroenterology. 2016.

  42. •• de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017;390(10098):959–68. https://doi.org/10.1016/S0140-6736(17)31327-2 This study is a prospective, multicenter, randomized trial using a unique remote monitoring platform to manage a population of inflammatory bowel disease patients.

    Article  PubMed  Google Scholar 

  43. Colombara F, Martinato M, Girardin G, Gregori D. Higher levels of knowledge reduce health care costs in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015. https://doi.org/10.1097/MIB.0000000000000304.

    Article  Google Scholar 

  44. Cross RK, Arora M, Finkelstein J. Acceptance of telemanagement is high in patients with inflammatory bowel disease. J Clin Gastroenterol. 2006. https://doi.org/10.1097/00004836-200603000-00006.

    Article  Google Scholar 

  45. Bilgrami Z, Abutaleb A, Chudy-Onwugaje K, Langenberg P, Regueiro M, Schwartz DA, et al. Effect of telemedicine for inflammatory bowel disease on patient activation and self-efficacy. Dig Dis Sci. 2019;65:96–103. https://doi.org/10.1007/s10620-018-5433-5.

    Article  PubMed  Google Scholar 

  46. •• Cross RK, Langenberg P, Regueiro M, et al. A randomized controlled trial of telemedicine for patients with inflammatory bowel disease (TELE-IBD). Am J Gastroenterol. 2018. https://doi.org/10.1038/s41395-018-0272-8 This study is a prospective, randomized trial evaluating the efficacy of telemedicine for the management of inflammatory bowel disease.

    Article  Google Scholar 

  47. Quinn CC, Chard S, Roth EG, Eckert JK, Russman KM, Cross RK. The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants’ perceptions. J Med Internet Res. 2019;21(6):e14165. https://doi.org/10.2196/14165.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Pedersen N, Elkjaer M, Duricova D, et al. EHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s disease. Aliment Pharmacol Ther. 2012. https://doi.org/10.1111/apt.12043.

    Article  CAS  Google Scholar 

  49. Helsel BC, Williams JE, Lawson K, Liang J, Markowitz J. Telemedicine and mobile health technology are effective in the management of digestive diseases: a systematic review. Dig Dis Sci. 2018;63:1392–408. https://doi.org/10.1007/s10620-018-5054-z.

    Article  PubMed  Google Scholar 

  50. Crandall W, Kappelman MD, Colletti RB, et al. ImproveCareNow: the development of a pediatric inflammatory bowel disease improvement network. Inflamm Bowel Dis. 2011. https://doi.org/10.1002/ibd.21394.

    Article  Google Scholar 

  51. Calvet X, Panés J, Alfaro N, Hinojosa J, Sicilia B, Gallego M, et al. Delphi consensus statement: quality indicators for inflammatory bowel disease comprehensive care units. J Crohns Colitis. 2014;8(3):240–51. https://doi.org/10.1016/j.crohns.2013.10.010.

    Article  PubMed  Google Scholar 

  52. ICHOM | Inflammatory bowel disease standard set | Measuring Outcomes. https://www.ichom.org/portfolio/inflammatory-bowel-disease/. Accessed 4 Nov 2019.

  53. Nguyen GC, Devlin SM, Afif W, Bressler B, Gruchy SE, Kaplan GG, et al. Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol. 2014;28(5):275–85. https://doi.org/10.1155/2014/941245.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic, Cleveland, OH, USA

    Jonathan A. Beard, Diana L. Franco & Benjamin H. Click

Authors
  1. Jonathan A. Beard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diana L. Franco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Benjamin H. Click
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin H. Click.

Ethics declarations

Conflict of Interest

Benjamin Click reports personal fees from Takeda Pharmaceuticals, outside the submitted work.

Jonathan Beard and Diana Franco declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Disclosures

BC serves on speakers’ bureau for Takeda.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Inflammatory Bowel Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beard, J.A., Franco, D.L. & Click, B.H. The Burden of Cost in Inflammatory Bowel Disease: A Medical Economic Perspective and the Future of Value-Based Care. Curr Gastroenterol Rep 22, 6 (2020). https://doi.org/10.1007/s11894-020-0744-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11894-020-0744-z

Keywords

Search

Navigation